Adebowale Akintayo
机构: Physician, Emory University
每年引用次数
引用次数
引用: 35
H-指数: 3
I10-指数 : 1
出版物: 5
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
Taofeek K. Owonikoko , Adeniyi K. Busari , Sungjin Kim , Zhengjia Chen
Oncology 95 ( 3) 138 -146
2
2018
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Taofeek Kunle Owonikoko , R Donald Harvey , John S Kauh , Colleen Margaret Lewis
Journal of Clinical Oncology 30 2576 -2576
4
2012
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
RD Harvey , TK Owonikoko , CM Lewis , A Akintayo
British Journal of Cancer 108 ( 4) 762 -765
21
2013
A phase 1 and pharmacokinetic study of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel in patients with advanced solid tumor malignancies
RD Harvey , CM Lewis , JS Kauh , TK Owonikoko
Poster presented at: European Society of Medical Oncology at the European Multidisciplinary Cancer Congress
1
2011
1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
R.D. Harvey , C.M. Lewis , J.S. Kauh , T.K. Owonikoko
European Journal of Cancer 47
6
2011